A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS in Women With Interstitial Cystitis Followed by an Open Label Extension

Trial Profile

A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS in Women With Interstitial Cystitis Followed by an Open Label Extension

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Interstitial cystitis
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 03 Apr 2013 According to a media release from TARIS, funding has been secured and phase 2 development of LiRIS will resume.
    • 01 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top